The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats.

W R Ravis, A K Valaer, D Brzozowski, C R Clark
Author Information
  1. W R Ravis: Department of Pharmacal Sciences, School of Pharmacy, Auburn University, Alabama 36849-5503.

Abstract

The metabolism and disposition of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) was studied by utilizing rat liver slices as well as by intravenous pharmacokinetic studies in rats. In the liver slice experiments, N-OH MDA (16 micrograms/ml) was incubated with rat liver slices and the disappearance of N-OH MDA and the appearance of MDA were observed over 2 hours. Drug and metabolites were assayed by a reverse phase high performance liquid chromatographic procedure including a C8 column and UV detection. N-OH MDA disappeared from the plasma at an apparent first-order rate with a t1/2 of 36.3 +/- 8.4 min. By the end of 2 hours, approximately 85% of the N-OH MDA was biotransformed to MDA. Following placement of jugular cannulas in rats, a dose of 15 mg/kg of N-OH MDA was administered intravenously. With rapid blood sampling, a t1/2 of 0.86 +/- 0.12 min was observed for N-OH MDA. A total body clearance of 9.09 +/- 2.06 L/hr/kg and a volume of distribution of 0.184 +/- 0.022 L/kg were noted. Plasma concentrations of MDA were observed after the N-OH MDA dose to rats. The MDA t1/2 after N-OH MDA dosing was 1.68 +/- 0.29 hours with peak plasma concentrations at 8 min. No other major metabolites could be detected in liver slice, plasma, or urine samples. Both sets of studies demonstrate the rapid conversion of N-OH MDA to MDA in rats.

MeSH Term

3,4-Methylenedioxyamphetamine
Animals
Biotransformation
Half-Life
In Vitro Techniques
Liver
Male
Metabolic Clearance Rate
Rats
Rats, Sprague-Dawley

Chemicals

3,4-Methylenedioxyamphetamine
N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane

Word Cloud

Created with Highcharts 10.0.0MDAN-OHliverrats+/-0observed2hoursplasmat1/2minmetabolismN-hydroxy-34-methylenedioxyamphetamineratslicesstudiesslicemetabolites8doserapidconcentrationsdispositionstudiedutilizingwellintravenouspharmacokineticexperiments16micrograms/mlincubateddisappearanceappearanceDrugassayedreversephasehighperformanceliquidchromatographicprocedureincludingC8columnUVdetectiondisappearedapparentfirst-orderrate3634endapproximately85%biotransformedFollowingplacementjugularcannulas15mg/kgadministeredintravenouslybloodsampling8612totalbodyclearance90906L/hr/kgvolumedistribution184022L/kgnotedPlasmadosing16829peakmajordetectedurinesamplessetsdemonstrateconversionpharmacokinetics

Similar Articles

Cited By